867291-41-6

Basic information

• Product Name: 4-(1-(4-nitrophenyl)piperidin-4-yl)morpholine
• Synonyms: 4-(1-(4-nitrophenyl)piperidin-4-yl)morpholine;4-[1-(4-nitrophenyl)-4-piperidinyl]morpholine
• CAS NO: 867291-41-6
• Molecular Formula: C₁₅H₂₁N₃O₃
• Molecular Weight: 291.34554
• Mol File: 867291-41-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(1-(4-nitrophenyl)piperidin-4-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-(4-nitrophenyl)piperidin-4-yl)morpholine(867291-41-6)
• EPA Substance Registry System: 4-(1-(4-nitrophenyl)piperidin-4-yl)morpholine(867291-41-6)

Safety Data

• Hazardous Substances Data: 867291-41-6(Hazardous Substances Data)

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 53617-35-9 4-(piperidin-4-yl)morpholine 
• 334942-10-8 4-(piperidin-4-yl)morpholine dihydrochloride 
• 125541-20-0 tert-butyl 4-(morpholin-4-yl)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 867291-42-7 4-(1-(4-aminophenyl)piperidin-4-yl)morpholine 

Relevant articles and documents

WEE1 inhibitors as well as preparation and application thereof

The invention relates to WEE1 inhibitors as well as preparation and application thereof. The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, and their use in the preparation of medicaments for the treatment of diseases associated with WEE1 activity.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.